Antisense Therapeutics Limited (ANP) is an Australian-based company operating mainly in the health care industry. Antisense is engaged in the creation, development and commercialisation of the antisense pharmaceuticals.
ChemGenex Pharmaceuticals (CXS) is an Australia-based biotechnology research and development company engaged in the improving patients' lives through the development of personalised therapeutics in the areas of obesity, cancer, depression and diabetes.
Genetic Technologies (GTG) is a life science company engaged in the licensing of biotechnology patents as well as specialising in the fields of genomics and genetics with operations in Canada, Switzerland and Australia.
Arana Therapeutics (AAH) is a global biopharmaceutical Company actively involved in the research, development, production and distribution of peptide based medical products for use in the pharmaceutical and veterinary industries.
Avexa (AVX) is a drug-discovery company principally engaged in the research and development of anti-infectives. Avexa's core focus is on the research, discovery and development of innovative medicines for the cure of the diseases caused by Human Immunodeficiency Virus (HIV) and Vancomycin- and methicillin-resistant bacteria.
Chemeq (CMQ) is a research driven veterinary pharmaceutical company engaged in the development, manufacturing and marketing of its product, CHEMEQ polymeric anti-microbial (CHEMEQ). CHEMEQ is used for the prevention and control of diseases caused in feedstock animals, like pigs and poultry by intestinal bacteria.
Clinuvel Pharmaceuticals (CUV) specialises in the manufacturing of biopharmaceuticals and prescription dermatology products. Clinuvel is engaged in the development of its innovative drug candidate afamelanotide.
Metabolic Pharmaceuticals (MBP) is a biotechnology company with around 300 million issued shares. The principal focus of the Company is to take innovative drugs, with strong market potential, through research, formal preclinical and clinical development.
Pharmaxis (PXS) is a pharmaceutical company specialising in the research, development and commercialisation of therapeutic pharmaceutical products. The Company manufactures specialty products for use in the diagnosis and treatment of chronic respiratory and immune disorders.
Sirtex Medical (SRX) is a biotechnology and medical device company. The Company is principally focused on the research and commercial development of liver cancer treatments using small particle technology. The Company supplies its product to a number of markets in Asia-Pacific, Europe and the United States of America.
Starpharma Holdings (SPL) is a world leading developer of nanotechnology-based pharmaceuticals operating in Australia and United States. The Company develops and commercialises dendrimer products for use in pharmaceutical, life-science and other applications.
BioSignal (BOS) was established to commercialise a proprietary technology based on anti-bacterial and anti-fouling compounds called "furanones" found in a seaweed. BOS's Furanones are naturally derived compounds that reduce a bacteria’s ability to attach to innate surfaces (such as pipes, ship hulls) and animate surfaces (such as lungs, skin and teeth).
Biotron Limited (BIT) was established to develop research projects on the basis of intellectual property (IP) developed at the Australian National University's John Curtin School of Medical Research (JCSMR).
Bone Medical (BNE), along with its subsidiaries, is engaged in the development of therapeutics to prevent and/or treat bone and joint diseases and conditions, especially osteoporosis, osteoarthritis and arthritis.
Giaconda (GIA) develop medical therapies that provides relief for patients suffering from serious gastointestinal (GI) diseases and disorders. Its product portfolio comprises of four therapeutic products and a pre-colonoscopy bowel preparation.
Helicon Group is involved in the business to identify and exploit niche market opportunities in the Biomedical markets in selected Asian markets with a China priority and to participate in the significant growth that has been projected for these markets over the next 25 years
Incitive (ICV) is a pharmaceuticals & biotechnology company. Its aim is to become a sustainable Life Science company by in-licensing leads at the discovery stage, taking them through preclinical studies which will create significant value-add, and partner with large pharmaceutical or biotechnology companies for the clinical phase.